James M. Kilts - Nov 16, 2020 Form 4/A - Amendment Insider Report for Viatris Inc (VTRS)

Role
Director
Signature
/s/ Kevin Macikowski, by power of attorney
Stock symbol
VTRS
Transactions as of
Nov 16, 2020
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/23/2022, 06:00 PM
Date Of Original Report
Nov 18, 2020
Next filing
Jun 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTRS Common Stock Award +35.8K +12772.86% 36K Nov 16, 2020 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2 Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F3 Includes 280 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

Remarks:

This filing amends a prior form filed on November 18, 2020 and does not represent any new transaction. The November 18, 2020 Form 4 filing incorrectly stated that 36,889 shares of Viatris common stock had been acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan; the actual number of shares was 35,764 as shown in the amended line item above. This amendment shall also serve to correct the corresponding amounts that were carried forward on Form 4 reports subsequently filed by the reporting person.